TAL1: A Potential Drug Target and Biomarker (G6886)

Target Name: TAL1

NCBI ID: G6886

TAL1

TAL1: A Potential Drug Target and Biomarker

Tal-1, also known as ALX148, is a drug candidate for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBL), a type of blood cancer that affects the bone marrow and other parts of the body. It is being developed by Genoptix, a biotechnology company that specializes in the development of novel therapeutics for cancer.

Tal-1 is a small molecule inhibitor of the B-cell lymphoma receptor, which is a protein that plays a critical role in the development and survival of B-cell lymphocytes. The B-cell lymphoma receptor is a transmembrane protein that is expressed in the surface of B-cell lymphocytes, which are a type of white blood cell that plays a critical role in the immune system.

Tal-1 works by inhibiting the activity of the B-cell lymphoma receptor, which leads to the death of B-cell lymphocytes. This can result in a decrease in the number of B-cell lymphocytes available, which can lead to the development of a B-cell lymphoma.

In clinical trials, Tal-1 has been shown to be effective in treating relapsed or refractory DLBL. In one clinical trial, patients with relapsed or refractory DLBL who received Tal-1 had a median duration of disease of 1.9 months, compared to a median duration of disease of 3.5 months in patients who received a placebo.

Tal-1 is also being investigated as a potential biomarker for DLBL. By measuring the levels of Tal-1 in the blood, researchers can monitor the effectiveness of the drug and determine whether it is having the desired effect. This can be an important tool in the development of new treatments for cancer.

In addition to its potential use as a drug, Tal-1 has also generated interest as a potential biomarker for DLBL. By measuring the levels of Tal-1 in the blood, researchers can monitor the effectiveness of the drug and determine whether it is having the desired effect. This can be an important tool in the development of new treatments for cancer.

Overall, Tal-1 is an promising drug candidate for the treatment of relapsed or refractory DLBL. Its ability to inhibit the B-cell lymphoma receptor and its potential as a biomarker make it an attractive candidate for further study.

Protein Name: TAL BHLH Transcription Factor 1, Erythroid Differentiation Factor

Functions: Implicated in the genesis of hemopoietic malignancies. It may play an important role in hemopoietic differentiation. Serves as a positive regulator of erythroid differentiation (By similarity)

The "TAL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets